Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T C Merigan

Showing results (351-360 of 366) with videos related to

Pageof 37
Sort By:
Journal of Virology|May 1, 1987
Native and recombinant herpes simplex virus type 1 envelope proteins induce human immune T-lymphocyte responsesJ W Torseth, G H Cohen, R J Eisenberg, et al.
The Journal of Infectious Diseases|January 1, 1997
Cytomegalovirus gB genotype distribution differs in human immunodeficiency virus-infected patients and immunocompromised allograft recipientsL Rasmussen, C Hong, D Zipeto, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 11, 1999
Frequency of class I HLA-restricted anti-HIV CD8+ T cells in individuals receiving highly active antiretroviral therapy (HAART)C M Gray, J Lawrence, J M Schapiro, et al.
Diabetologia|August 1, 1981
Human leukocyte interferon treatment of two children with insulin dependent diabetesK H Rand, A L Rosenbloom, N K Maclaren, et al.
The Journal of Infectious Diseases|June 1, 1996
A randomized, placebo-controlled study of the immunogenicity of human immunodeficiency virus (HIV) rgp160 vaccine in HIV-infected subjects with > or = 400/mm3 CD4 T lymphocytes (AIDS Clinical Trials Group Protocol 137)F T Valentine, S Kundu, P A Haslett, et al.
AIDS Research and Human Retroviruses|October 6, 2000
Highly active antiretroviral therapy results in HIV type 1 suppression in lymph nodes, increased pools of naive T cells, decreased pools of activated T cells, and diminished frequencies of peripheral activated HIV type 1-specific CD8+ T cellsC M Gray, J Lawrence, E A Ranheim, et al.
Circulation|July 7, 1999
Impact of prophylactic immediate posttransplant ganciclovir on development of transplant atherosclerosis: a post hoc analysis of a randomized, placebo-controlled studyH A Valantine, S Z Gao, S G Menon, et al.
The New England Journal of Medicine|October 10, 1996
The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study TeamD A Katzenstein, S M Hammer, M D Hughes, et al.
The Journal of Infectious Diseases|July 1, 1982
Infectious Diseases Society of America. Trials of interferon therapy for multiple sclerosisJ Abb, F Deinhardt, H Zander, et al.
Annals of Internal Medicine|July 1, 1982
Cytomegalovirus immune plasma in bone marrow transplant recipientsD J Winston, R B Pollard, W G Ho, et al.
Pageof 37

Showing results (351-360 of 366) with videos related to

Sort By:
Pageof 37
Journal of Virology|May 1, 1987
Native and recombinant herpes simplex virus type 1 envelope proteins induce human immune T-lymphocyte responsesJ W Torseth, G H Cohen, R J Eisenberg, et al.
The Journal of Infectious Diseases|January 1, 1997
Cytomegalovirus gB genotype distribution differs in human immunodeficiency virus-infected patients and immunocompromised allograft recipientsL Rasmussen, C Hong, D Zipeto, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 11, 1999
Frequency of class I HLA-restricted anti-HIV CD8+ T cells in individuals receiving highly active antiretroviral therapy (HAART)C M Gray, J Lawrence, J M Schapiro, et al.
Diabetologia|August 1, 1981
Human leukocyte interferon treatment of two children with insulin dependent diabetesK H Rand, A L Rosenbloom, N K Maclaren, et al.
The Journal of Infectious Diseases|June 1, 1996
A randomized, placebo-controlled study of the immunogenicity of human immunodeficiency virus (HIV) rgp160 vaccine in HIV-infected subjects with > or = 400/mm3 CD4 T lymphocytes (AIDS Clinical Trials Group Protocol 137)F T Valentine, S Kundu, P A Haslett, et al.
AIDS Research and Human Retroviruses|October 6, 2000
Highly active antiretroviral therapy results in HIV type 1 suppression in lymph nodes, increased pools of naive T cells, decreased pools of activated T cells, and diminished frequencies of peripheral activated HIV type 1-specific CD8+ T cellsC M Gray, J Lawrence, E A Ranheim, et al.
Circulation|July 7, 1999
Impact of prophylactic immediate posttransplant ganciclovir on development of transplant atherosclerosis: a post hoc analysis of a randomized, placebo-controlled studyH A Valantine, S Z Gao, S G Menon, et al.
The New England Journal of Medicine|October 10, 1996
The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study TeamD A Katzenstein, S M Hammer, M D Hughes, et al.
The Journal of Infectious Diseases|July 1, 1982
Infectious Diseases Society of America. Trials of interferon therapy for multiple sclerosisJ Abb, F Deinhardt, H Zander, et al.
Annals of Internal Medicine|July 1, 1982
Cytomegalovirus immune plasma in bone marrow transplant recipientsD J Winston, R B Pollard, W G Ho, et al.
Pageof 37